Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Diabetes

SGLT2 inhibitors linked to reduced risk of serious renal events

Research has provided further support for the use of sodium–glucose co-transporter 2 inhibitors in a broad range of patients with type 2 diabetes mellitus.

Fingerprick test ss20

Source: Shutterstock.com

Sodium–glucose co-transporter 2 inhibitors have been shown to protect renal function in people with type 2 diabetes mellitus who also have nephropathy or are at high cardiovascular risk

Sodium–glucose co-transporter 2 (SGLT2) inhibitors are associated with a lower incidence of serious renal events in people with diabetes compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, which were used as an active comparator, a study in the BMJ has suggested (29 April 2020)[1].

Researchers looked at data from nationwide registries of Sweden, Denmark and Norway, from between 2013 and 2018, including 29,887 new users of SGLT2 inhibitors matched to an equal number of new users of DPP-4 inhibitors.

Over a mean follow-up of 1.7 years, people taking SGLT2 inhibitors were 58% less likely to experience serious renal events than those taking DPP-4 inhibitors (2.6 vs. 6.2 events per 1,000 person-years; hazard ratio 0.42, 95% confidence interval 0.34–0.53). They were also significantly less likely to require renal replacement therapy or be admitted to hospital for a renal event.

In clinical trials, SGLT2 inhibitors have been shown to protect renal function in people with type 2 diabetes mellitus who also have nephropathy or are at high cardiovascular risk. However, it has not been shown how this translates to serious renal events in the wider population of people with diabetes.

“Complementing data from clinical trials, this study provides further support for the use of SGLT2 inhibitors in a broad range of patients with type 2 diabetes mellitus,” they concluded. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208050

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.